Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.PH)

ARWR.PH on Philadelphia Stock Exchange

1.43USD
2 Dec 2016
Change (% chg)

$0.10 (+7.52%)
Prev Close
$1.33
Open
$1.35
Day's High
$1.46
Day's Low
$1.34
Volume
13,584
Avg. Vol
7,664
52-wk High
$8.21
52-wk Low
$1.33

ARWR.PH

Chart for ARWR.PH

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus... (more)

Overall

Beta: 2.32
Market Cap(Mil.): $264.26
Shares Outstanding(Mil.): 60.75
Dividend: --
Yield (%): --

Financials

  ARWR.PH Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.41 -- --
ROI: -81.21 -1.09 14.95
ROE: -88.08 -2.39 16.29

Arrowhead Pharma sinks after shelving three drug programs

Shares of Arrowhead Pharmaceuticals Inc sank more than 60 percent in premarket trading on Wednesday, a day after the company said it would stop developing all drugs being tested on humans due to a setback in its drug-delivery technology.

Nov 30 2016

BRIEF-Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

* Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

Nov 29 2016

BRIEF-Arrowhead Pharmaceuticals provides update on Heparc-2004

* Notified verbally by United States FDA of its decision to place a clinical hold on heparc-2004

Nov 08 2016

BRIEF-Arrowhead Pharmaceuticals files for mixed shelf of up to $200 mln - SEC filing

* Files for mixed shelf of up to $200 million - SEC filing Source text: (http://bit.ly/2e5NfCw) Further company coverage:

Oct 28 2016

BRIEF-Arrowhead Pharma files for sale of aggregate of 3 mln shares of co's common stock by selling shareholder Amgen

* Arrowhead Pharmaceuticals Inc - Files for sale of aggregate of 3.0 million shares of co's common stock by selling shareholder Amgen Inc - SEC filing

Oct 28 2016

BRIEF-Arrowhead and Spring Bank report clinical collaboration

* Arrowhead And Spring Bank Announce Clinical Collaboration For Arc-520 and SB 9200 in chronic hepatitis B

Oct 06 2016

Amgen, Arrowhead team up on gene-therapies for heart disease

Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

Sep 29 2016

UPDATE 1-Amgen, Arrowhead team up on gene-therapies for heart disease

Sept 29 Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

Sep 29 2016

Amgen and Arrowhead to develop gene-therapies for heart disease

Sept 29 Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and team up with the company to develop gene-silencing therapies for heart disease.

Sep 29 2016

BRIEF-Arrowhead Pharmaceuticals announces sale of about 7.6 mln shares

* Sale of an aggregate of 7.6 million shares of common stock, $0.001 par value per share by selling stockholders - sec filing Source text for Eikon: Further company coverage:

Sep 02 2016

Earnings vs. Estimates